IMMUNOHISTOLOGICAL STUDY OF MONONUCLEAR CELL INFILTRATE IN MALIGNANT GLIOMAS
IMMUNOHISTOLOGICAL STUDY OF MONONUCLEAR CELL INFILTRATE IN MALIGNANT GLIOMAS
复制标题
DOI：
10.1007/bf00688191
复制
发表时间：
1987-01-01
影响因子：
12.7
通讯作者：
BROWNELL, DB
中科院分区：
文献类型：
--
作者：
ROSSI, ML;HUGHES, JT;BROWNELL, DB
65例恶性胶质瘤（星形细胞瘤3级和4级和胶质母细胞瘤）进行了检查，通过免疫过氧化物酶染色的冷冻组织使用各种单克隆抗体针对巨噬细胞，淋巴细胞和自然杀伤细胞。根据使用的抗体，肿瘤中巨噬细胞的存在范围为85% -100%。正如预期的那样，许多肿瘤不仅在坏死区域而且在完整的肿瘤组织中含有大量的巨噬细胞。89%的39个肿瘤检测含有Fc受体承载单核细胞在活的肿瘤。在100%的44个肿瘤检测HLADR 2类主要组织相容性复合物抗原，这种抗原在巨噬细胞中检测到。在这44例中，40%的肿瘤细胞上也存在HLA-DR抗原。88%的53个肿瘤测试含有T细胞在活的肿瘤和这些细胞的大部分是T细胞毒性/抑制（T8）。33个肿瘤中有24%不含T辅助/诱导（T4）淋巴细胞，其他76%的肿瘤中几乎没有阳性细胞。21种肿瘤中只有9%含有自然杀伤细胞（NK）。B细胞在61个肿瘤中的88%中不存在，并且几乎所有其余肿瘤仅含有少量B细胞。研究结果进行了讨论，参考可能的宿主对胶质瘤的免疫反应和相关文献进行了综述。
Sixty-five malignant gliomas (astrocytomas grade 3 and 4 and glioblastomas) were examined by means of immunoperoxidase staining on frozen tissue using various monoclonal antibodies directed against macrophages, lymphocytes and natural killer cells. Depending on the antibody used, the presence of macrophages in tumours ranged from 85% - 100%. Many of the tumours contained substantial numbers of macrophages not only, as expected, in necrotic areas but also in intact tumour tissue. Eightly-nine percent of 39 tumours tested contained Fc receptor-bearing mononuclear cells in viable tumour. In 100% of 44 tumours tested for HLADR class 2 major histocompatibility complex antigen this antigen was detected in the macrophages. In 40% of these 44 cases, HLADR antigen was also present on the tumour cells. Eighty-eight percent of 53 tumours tested contained T cells in viable tumour and the majority of these cells were T cytotoxic/suppressor (T8). Twenty-four percent of 33 tumours contained no T helper/inducer (T4) lymphocytes and in the other 76% there were few positive cells. Only 9% of 21 tumours contained natural killer cells (NK). B cells were absent from 88% of 61 tumours and almost all of the remainder contained only a small number of B cells. The findings are discussed with reference to a possible host immune response to gliomas and relevant literature is reviewed.